Pipeline Overview

Program
Target
Indications
Discovery
Pre-clinical development
Early phase
Rights
Program: CFT1946
Target: BRAF V600
Indications V600 Mutant Cancers
Early phase
Right 1
Program: CFT8919*
Target: EGFR L858R
Pre-clinical
Right 1 Right 2
Program: Undisclosed
Indications Various Cancers
Discovery
Right 1
Program: Undisclosed
Indications Various Cancers
Discovery
Right 1
Program: Undisclosed
Indications Various Cancers
Discovery
Right 1

*Exclusive License and Collaboration Agreement with Betta Pharmaceuticals for the development and commercialization in Greater China

Learn more about our partnerships